METformin for the MINimization of Geographic Atrophy Progression (METforMIN): A Randomized Trial.

ABSTRACT:

Purpose

Metformin use has been associated with a decreased risk of age-related macular degeneration (AMD) progression in observational studies. We aimed to evaluate the efficacy of oral metformin for slowing geographic atrophy (GA) progression.

Design

Parallel-group, multicenter, randomized phase II clinical trial.

Participants

Participants aged ≥ 55 years without diabetes who had GA from atrophic AMD in ≥ 1 eye.

Methods

We enrolled participants across 12 clinical centers and randomized participants in a 1:1 ratio to receive oral metformin (2000 mg daily) or observation for 18 months. Fundus autofluorescence imaging was obtained at baseline and every 6 months.

Main outcome measures

The primary efficacy endpoint was the annualized enlargement rate of the

SUBMITTER: Shen LL 

PROVIDER: S-EPMC10810745 | biostudies-literature | 2024 May-Jun

REPOSITORIES: biostudies-literature